Global Diabetic Kidney Disease Market Size Study, by Drug Class, by Route of Administration, by Distribution Channel, and Regional Forecasts 2022-2032

Description

Global diabetic kidney disease market is valued at approximately USD 2.89 billion in 2023 and is anticipated to grow at a steady CAGR of 4.8% over the forecast period from 2024 to 2032, reaching a projected market size of USD 4.21 billion by 2032. Diabetic kidney disease, a severe complication of diabetes, occurs when high blood sugar levels cause damage to the kidneys' blood vessels. This leads to impaired kidney function, resulting in the accumulation of waste in the body and potentially severe health issues. As the prevalence of diabetes continues to rise globally, the diabetic kidney disease market is witnessing significant growth, driven by the increasing awareness of the disease, the availability of advanced treatment options, and developments in diagnostic tools and renal replacement therapies.

The market's growth is primarily fueled by the sharp increase in the global diabetic population, which correlates with a higher incidence of diabetic kidney disease. As lifestyle habits change and physical activity decreases, more individuals are being diagnosed with diabetes, elevating their risk of developing kidney complications. The aging global population further exacerbates this trend, as older individuals are more susceptible to chronic conditions, including diabetic kidney disease, due to long-standing diabetes. Healthcare systems are now faced with the challenge of managing this growing burden, which is driving the demand for effective treatments and early diagnostic tools.

However, the market faces several challenges, including the high cost of treatment devices and a lack of awareness in low-income regions. These barriers can limit access to care, especially in developing countries where healthcare resources are limited. Despite these challenges, the market presents lucrative opportunities, particularly in regions experiencing rapid economic growth and urbanization, such as Asia-Pacific and Latin America. The rising prevalence of diabetes in these regions, coupled with increased healthcare spending, is expected to drive market expansion over the forecast period.

North America has been the dominant region in the global diabetic kidney disease market, with the U.S. holding the largest share due to its high prevalence of diabetes and access to advanced healthcare. The region's economic capabilities and well-developed healthcare infrastructure have led to significant investments in research and development, resulting in innovative treatments and early adoption of new therapies. Meanwhile, the Asia-Pacific region is emerging as the fastest-growing market, driven by rapid urbanization, increasing awareness of diabetes-related complications, and the availability of affordable generic drugs.

Major market players included in this report are:

AstraZeneca
Boehringer Ingelheim
Janssen Pharmaceuticals
Bristol Myers Squibb
GSK
Novo Nordisk
Eli Lilly and Company
Merck & Co.
Sanofi
AbbVie
Sun Pharmaceutical Industries Ltd
Teva Pharmaceutical Industries Ltd
Lupin
Aurobindo Pharma
Takeda Pharmaceutical Company Limited

The detailed segments and sub-segment of the market are explained below:

By Drug Class

Angiotensin Receptor Blockers (ARBs)
Calcium Channel Blockers
Antioxidant Inflammation Modulator
Angiotensin-Converting Enzyme (ACE) Inhibitors
Others

By Route of Administration

Oral
Parenteral

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

By Region:

North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
RoLA
Middle East & Africa
Saudi Arabia
South Africa
RoMEA

Years considered for the study are as follows:

Historical year - 2022
Base year - 2023
Forecast period - 2024 to 2032

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2031.
Annualized revenues and regional-level analysis for each market segment.
Detailed analysis of the geographical landscape with country-level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of the competitive structure of the market.
Demand-side and supply-side analysis of the market.

Chapter 1. Global Diabetic Kidney Disease Market Executive Summary

1.1. Global Diabetic Kidney Disease Market Size & Forecast (2022-2032)
1.2. Regional Summary
1.3. Segmental Summary
- 1.3.1. By Drug Class
- 1.3.2. By Route of Administration
- 1.3.3. By Distribution Channel
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Diabetic Kidney Disease Market Definition and Research Assumptions

2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
- 2.3.1. Inclusion & Exclusion
- 2.3.2. Limitations
- 2.3.3. Supply Side Analysis
  - 2.3.3.1. Availability
  - 2.3.3.2. Infrastructure
  - 2.3.3.3. Regulatory Environment
  - 2.3.3.4. Market Competition
  - 2.3.3.5. Economic Viability (Consumer's Perspective)
- 2.3.4. Demand Side Analysis
  - 2.3.4.1. Regulatory frameworks
  - 2.3.4.2. Technological Advancements
  - 2.3.4.3. Environmental Considerations
  - 2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates

Chapter 3. Global Diabetic Kidney Disease Market Dynamics

3.1. Market Drivers
- 3.1.1. Rising Prevalence of Diabetes
- 3.1.2. Increasing Geriatric Population
- 3.1.3. Technological Advancements in Diagnostics and Treatment
3.2. Market Challenges
- 3.2.1. High Treatment Costs
- 3.2.2. Lack of Awareness in Low-Income Regions
3.3. Market Opportunities
- 3.3.1. Growth in Healthcare Investments in Emerging Markets
- 3.3.2. Increasing Focus on Early Screening Programs
- 3.3.3. Development of New Molecular Entities

Chapter 4. Global Diabetic Kidney Disease Market Industry Analysis

4.1. Porter's 5 Force Model
- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's 5 Force Model
- 4.1.7. Porter's 5 Force Impact Analysis
4.2. PESTEL Analysis
- 4.2.1. Political
- 4.2.2. Economical
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal
4.3. Top Investment Opportunity
4.4. Top Winning Strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Diabetic Kidney Disease Market Size & Forecasts by Drug Class 2022-2032

5.1. Segment Dashboard
5.2. Global Diabetic Kidney Disease Market: Drug Class Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 5.2.1. Angiotensin Receptor Blockers (ARBs)
- 5.2.2. Calcium Channel Blockers
- 5.2.3. Antioxidant Inflammation Modulator
- 5.2.4. Angiotensin-Converting Enzyme (ACE) Inhibitors
- 5.2.5. Others

Chapter 6. Global Diabetic Kidney Disease Market Size & Forecasts by Route of Administration 2022-2032

6.1. Segment Dashboard
6.2. Global Diabetic Kidney Disease Market: Route of Administration Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 6.2.1. Oral
- 6.2.2. Parenteral

Chapter 7. Global Diabetic Kidney Disease Market Size & Forecasts by Distribution Channel 2022-2032

7.1. Segment Dashboard
7.2. Global Diabetic Kidney Disease Market: Distribution Channel Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 7.2.1. Hospital Pharmacies
- 7.2.2. Retail Pharmacies
- 7.2.3. Online Pharmacies

Chapter 8. Global Diabetic Kidney Disease Market Size & Forecasts by Region 2022-2032

8.1. North America Diabetic Kidney Disease Market
- 8.1.1. U.S. Diabetic Kidney Disease Market
  - 8.1.1.1. Drug Class breakdown size & forecasts, 2022-2032
  - 8.1.1.2. Route of Administration breakdown size & forecasts, 2022-2032
  - 8.1.1.3. Distribution Channel breakdown size & forecasts, 2022-2032
- 8.1.2. Canada Diabetic Kidney Disease Market
  - 8.1.2.1. Drug Class breakdown size & forecasts, 2022-2032
  - 8.1.2.2. Route of Administration breakdown size & forecasts, 2022-2032
  - 8.1.2.3. Distribution Channel breakdown size & forecasts, 2022-2032
8.2. Europe Diabetic Kidney Disease Market
- 8.2.1. U.K. Diabetic Kidney Disease Market
- 8.2.2. Germany Diabetic Kidney Disease Market
- 8.2.3. France Diabetic Kidney Disease Market
- 8.2.4. Spain Diabetic Kidney Disease Market
- 8.2.5. Italy Diabetic Kidney Disease Market
- 8.2.6. Rest of Europe Diabetic Kidney Disease Market
8.3. Asia-Pacific Diabetic Kidney Disease Market
- 8.3.1. China Diabetic Kidney Disease Market
- 8.3.2. India Diabetic Kidney Disease Market
- 8.3.3. Japan Diabetic Kidney Disease Market
- 8.3.4. Australia Diabetic Kidney Disease Market
- 8.3.5. South Korea Diabetic Kidney Disease Market
- 8.3.6. Rest of Asia Pacific Diabetic Kidney Disease Market
8.4. Latin America Diabetic Kidney Disease Market
- 8.4.1. Brazil Diabetic Kidney Disease Market
- 8.4.2. Mexico Diabetic Kidney Disease Market
- 8.4.3. Rest of Latin America Diabetic Kidney Disease Market
8.5. Middle East & Africa Diabetic Kidney Disease Market
- 8.5.1. Saudi Arabia Diabetic Kidney Disease Market
- 8.5.2. South Africa Diabetic Kidney Disease Market
- 8.5.3. Rest of Middle East & Africa Diabetic Kidney Disease Market

Chapter 9. Competitive Intelligence

9.1. Key Company SWOT Analysis
9.2. Top Market Strategies
9.3. Company Profiles
- 9.3.1. AstraZeneca
  - 9.3.1.1. Key Information
  - 9.3.1.2. Overview
  - 9.3.1.3. Financial (Subject to Data Availability)
  - 9.3.1.4. Product Summary
  - 9.3.1.5. Market Strategies
- 9.3.2. Boehringer Ingelheim
- 9.3.3. Janssen Pharmaceuticals
- 9.3.4. Bristol Myers Squibb
- 9.3.5. GSK
- 9.3.6. Novo Nordisk
- 9.3.7. Eli Lilly and Company
- 9.3.8. Merck & Co.
- 9.3.9. Sanofi
- 9.3.10. AbbVie
- 9.3.11. Sun Pharmaceutical Industries Ltd
- 9.3.12. Teva Pharmaceutical Industries Ltd
- 9.3.13. Lupin
- 9.3.14. Aurobindo Pharma
- 9.3.15. Takeda Pharmaceutical Company Limited

Chapter 10. Research Process

10.1. Research Process
- 10.1.1. Data Mining
- 10.1.2. Analysis
- 10.1.3. Market Estimation
- 10.1.4. Validation
- 10.1.5. Publishing
10.2. Research Attributes